Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia (APHERESE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 0A6
- Institute of Nutrition and Functional Foods (INAF)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged between 18-65 years
- Subjects with homozygous familial hypercholesterolemia:
- Carrier of a mutation in the LDL receptor gene
Exclusion Criteria:
- Subjects with a previous history of cardiovascular disease
- Subjects with Type 2 diabetes
- Were pregnant or nursing;
- Subjects with a history of cancer
- Subjects with acute liver disease, hepatic dysfunction, or persistent elevations of serum transaminases
- Subjects with a secondary hyperlipidemia due to any cause
- History of alcohol or drug abuse within the past 2 years
- hormonal treatment
- Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
heparin-induced extracorporeal LDL precipitation
Lipid apheresis treatment for 3 hours
|
Lipid apheresis for 3 hours
Other Names:
|
|
dextran sulfate adsorption
Lipid apheresis treatment for 3 hours
|
Lipid apheresis for 3 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in plasma lipid levels between the two lipid apheresis treatment
Time Frame: At the end of the two lipid apheresis (Week 0 and 2)
|
At the end of the two lipid apheresis (Week 0 and 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in plasma adhesion molecule levels between the two lipid apheresis treatment
Time Frame: At the end of the two lipid apheresis (Week 0 and 2)
|
At the end of the two lipid apheresis (Week 0 and 2)
|
|
Change in plasma inflammatory marker levels between the two lipid apheresis treatment
Time Frame: At the end of the two lipid apheresis (Week 0 and 2)
|
At the end of the two lipid apheresis (Week 0 and 2)
|
|
Change in LDL particle size between the two lipid apheresis treatment
Time Frame: At the end of the two lipid apheresis (Week 0 and 2)
|
At the end of the two lipid apheresis (Week 0 and 2)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemias
- Hypercholesterolemia
- Hyperlipoproteinemia Type II
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Plasma Substitutes
- Blood Substitutes
- Heparin
- Dextrans
Other Study ID Numbers
Other Study ID Numbers
- APHERESE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.